Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Altimmune Inc
(NQ:
ALT
)
6.960
+0.580 (+9.09%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Altimmune Inc
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Decoding 4 Analyst Evaluations For Altimmune
August 22, 2024
Via
Benzinga
3 Promising Biotech Stocks for the Long-Term: August 2024
August 13, 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.
Via
InvestorPlace
The 7 Best Under $10 Stocks to Buy in August 2024
August 11, 2024
Buying low-priced stocks carries risk, but lower interest rates may lower the risk premium on these best stocks under $10.
Via
InvestorPlace
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
August 09, 2024
Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space.
Via
The Motley Fool
ALT Stock Earnings: Altimmune Misses EPS for Q2 2024
August 08, 2024
ALT stock results show that Altimmune missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
August 07, 2024
From
CytoSorbents
Via
GlobeNewswire
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
August 02, 2024
The popularity surrounding weight loss drugs such as Mounjaro and Ozempic has brought Eli Lilly and Novo Nordisk newfound growth.
Via
The Motley Fool
ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
July 30, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
July 20, 2024
At least one of the pair has a credible shot at finding a home in the market.
Via
The Motley Fool
3 Undervalued Biotech Stocks With Breakout Potential
July 19, 2024
Invest in these three undervalued biotech stocks with double-digit upside ahead driven by cutting-edge healthcare advancements
Via
InvestorPlace
Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio
July 17, 2024
These three wild-card stocks will spice up your portfolio in ways boring diversification never could, so read on.
Via
InvestorPlace
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
July 10, 2024
Both competitors have promising lead programs, and enough cash, too.
Via
The Motley Fool
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
July 09, 2024
Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been
Via
MarketBeat
7 Bullish Stock Picks With the Potential to Turn $5K Into $50K
July 09, 2024
These high-potential stock picks each have 10X potential moving forward and are well worth understanding despite high prices in some cases.
Via
InvestorPlace
The 7 Best Under $10 Stocks to Buy in July 2024
July 06, 2024
We’re finding big opportunities in some of the best stocks under $10 a share. In fact, here are seven you may want to jump into now.
Via
InvestorPlace
MarketBeat Week in Review – 7/1 - 7/5
July 06, 2024
The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, Harbor Diversified, Altimmune, and Sprout Social and Encourages Investors to Contact the Firm
July 04, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
July 04, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
ALTIMMUNE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Altimmune, Inc. and Encourages Investors to Contact the Firm
July 03, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altimmune, Inc. (ALT)
July 03, 2024
From
Law Offices of Frank R. Cruz
Via
Business Wire
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
July 03, 2024
Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases
Via
MarketBeat
Exposures
Product Safety
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
July 02, 2024
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy
Via
MarketBeat
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
July 01, 2024
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound.
Via
MarketBeat
Exposures
Product Safety
ALTIMMUNE, INC. (NASDAQ: ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of Upcoming Deadline
July 01, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, AXT, Harbor Diversified, and Altimmune and Encourages Investors to Contact the Firm
June 30, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
June 30, 2024
While their share prices have traveled different paths recently, the similarity between the two companies is striking.
Via
The Motley Fool
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
June 29, 2024
The market for weight loss medicines keeps getting hotter and hotter.
Via
The Motley Fool
Lowey Dannenberg Notifies Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
June 28, 2024
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
June 28, 2024
With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs.
Via
InvestorPlace
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
June 28, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.